KPTIHIGH SIGNALFINANCIAL10-K

KPTI faces severe liquidity constraints with funding only expected through Q2 2026, while net losses nearly tripled and stockholder equity deteriorated to -$292.9M.

The company has added explicit language stating liquidity will only last into Q2 2026 and strengthened warnings about potential strategic alternatives, indicating mounting financial pressure. The dramatic worsening of net income despite improved operating performance suggests significant non-operating charges, while the substantial decline in stockholder equity to deeply negative territory signals potential distress.

Comparing 2026-02-13 vs 2025-02-19View on EDGAR →
FINANCIAL ANALYSIS

Despite operational improvements with operating losses narrowing 24% and operating cash flow improving 41%, KPTI's overall financial position deteriorated sharply with net losses ballooning 157% to -$196M. Total assets declined 34% to $108.4M while liabilities increased 15% to $401.3M, driving stockholder equity deeper into negative territory at -$292.9M. The disconnect between improved operations and worsening net income, combined with shrinking assets and rising liabilities, suggests significant financial stress requiring immediate attention from management and investors.

FINANCIAL STATEMENT CHANGES
Net Income
P&L
-156.5%
-$76.4M→-$196.0M

Net income declined 156.5% — review whether driven by operations, interest costs, or non-recurring items.

Stockholders Equity
Balance Sheet
-57.5%
-$186.0M→-$292.9M

Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.

Operating Cash Flow
Cash Flow
+40.9%
-$127.5M→-$75.4M

Operating cash flow surged 40.9% — exceptional cash generation, highest quality earnings signal.

Total Assets
Balance Sheet
-34.1%
$164.4M→$108.4M

Total assets contracted 34.1% — asset sales, write-downs, or balance sheet optimization underway.

Current Assets
Balance Sheet
-34.1%
$156.5M→$103.1M

Current assets declined 34.1% — monitor working capital adequacy and short-term liquidity.

Operating Income
P&L
+24.1%
-$119.4M→-$90.7M

Operating income improving — cost discipline or growing revenue base absorbing fixed costs.

Inventory
Balance Sheet
-14.8%
$4.7M→$4.0M

Inventory reduced 14.8% — lean inventory management or demand outpacing supply.

Total Liabilities
Balance Sheet
+14.5%
$350.4M→$401.3M

Liabilities increased 14.5% — monitor debt-to-equity ratio and interest coverage.

R&D Expense
P&L
-12.3%
$143.2M→$125.6M

R&D spending cut 12.3% — could signal cost discipline or concerning reduction in innovation investment.

LANGUAGE CHANGES
NEW — 2026-02-13
PRIOR — 2025-02-19
ADDED
We believe that our existing liquidity, including cash, cash equivalents and investments, as well as cash flow from net product revenue and license and other revenue, will only enable us to fund our current operating plans into the second quarter of 2026.
We may never achieve or maintain profitability and will need additional funding or to enter into strategic alternatives to achieve our business objectives.
We may not be able to satisfy our indebtedness or comply with various covenants and other provisions under our credit agreement and the indentures under outstanding convertible notes, on a timely basis or at all.
If we or our collaborators are unable to successfully commercialize current and future indications of XPOVIO or other products or product candidates on a timely basis, our business, financial condition and future profitability will be materially harmed.
We face substantial competition for XPOVIO in multiple myeloma and will face competition for selinexor in any additional indications for which it may be approved.
+7 more — sign up free →
REMOVED
If we or our collaborators are unable to successfully commercialize current and future indications of XPOVIO or other products or product candidates, our business, financial condition and future profitability will be materially harmed.
Serious adverse or unacceptable side effects related to XPOVIO, our product candidates or future products may delay or prevent their regulatory approval, cause us to suspend or discontinue clinical trials, or limit the commercial value of our approved indications.
The results of previous clinical trials may not be predictive of future trial results and interim or top-line data may be subject to change or qualification.
and international trade policies, particularly with respect to China, may adversely impact our business.
We may never achieve or maintain profitability and will need additional funding to achieve our business objectives.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →